Aminotransferse Levels are not Predictive of Histologic Activity or Stage in Morbidly Obese Patients with Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)

被引：0

作者：

Birerdinc, Aybike ^{[1
]}

Lei, Wang ^{[2
]}

Ozcan, Kenan ^{[2
]}

Nguyenngo, Cartherine ^{[2
]}

Estep, Michael ^{[1
]}

Afendy, Arian ^{[1
]}

Baranova, Ancha ^{[1
]}

Younossi, Zobair ^{[3
]}

机构：

[1] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA USA

[2] George Mason Univ, Coll Sci, Sch Syst Biol, Fairfax, VA 22030 USA

[3] Inova Fairfax Hosp, Dept Med, Ctr Liver Dis, Falls Church, VA USA

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2011年 / 106卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

294

引用

页码：S116 / S117

页数：2

共 50 条

[1] Non-alcoholic fatty liver disease (NAFLD). Non-alcoholic steatohepatitis - NASH
Keller, KM
MONATSSCHRIFT KINDERHEILKUNDE, 2004, 152 (08) : 864 - 869
[2] Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment
Bugianesi, E
Marzocchi, R
Villanova, N
Marchesini, G
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2004, 18 (06) : 1105 - 1116
[3] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
Jürgen Kurt Rockstroh
Current HIV/AIDS Reports, 2017, 14 : 47 - 53
[4] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
Rockstroh, Juergen Kurt
CURRENT HIV/AIDS REPORTS, 2017, 14 (02) : 47 - 53
[5] Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)
Verma, Siddharth
Jensen, Donald
Hart, John
Mohanty, Smruti R.
LIVER INTERNATIONAL, 2013, 33 (09) : 1398 - 1405
[6] Non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD) - A growing epidemic
South, K
GASTROENTEROLOGY NURSING, 2006, 29 (02) : 169 - 169
[7] Design and validation of a histologic scoring system for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Kleiner, DE
Brunt, EM
Van Natta, ML
Behling, C
Contos, MJ
Cummings, OW
Ferrell, LD
Liu, YC
Torbenson, MS
Yeh, M
McCullough, AJ
Sanyal, AJ
HEPATOLOGY, 2003, 38 (04) : 233A - 233A
[8] Non-alcoholic Fatty Liver Disease (NAFLD) and non-alcoholic Steatohepatitis (NASH): Pathophysiology and Nutritional Aspects
Schattenberg, Joern M.
ERNAHRUNGS UMSCHAU, 2015, 62 (02): : M92 - M100
[9] Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course
Cortez-Pinto, H
Camilo, ME
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2004, 18 (06) : 1089 - 1104
[10] Linagliptin is an Effective Therapeutic for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)
Klein, Thomas
Mark, Michael
DIABETES, 2012, 61 : A265 - A266

← 1 2 3 4 5 →